Isolation and structural determination of phepropeptins A, B, C, and D, new proteasome inhibitors, produced by Streptomyces sp.

Journal of Antibiotics

Volumn 54, Issue 11, 2001, Pages 874-881

  Sekizawa, R ^a   Momose, I ^a   Kinoshita, N ^a   Naganawa, H ^a   Hamada, M ^a   Muraoka, Y ^a   Iinuma, H ^a   Takeuchi, T ^a  

^a INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CHEMICAL COMPOUND; CHYMOTRYPSIN; CHYMOTRYPSIN A; EPOXOMICIN; HEXAPEPTIDE; LACTACYSTIN; PEPTIDE; PHEPROPEPTIN A; PHEPROPEPTIN B; PHEPROPEPTIN C; PHEPROPEPTIN D; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STREPTOMYCES;

STREPTOMYCES;

EID: 0035211024     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.7164/antibiotics.54.874     Document Type: Article

References (13)

1. The multicatalytic and 26S proteases
2. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids
3. The ubiquitin system
4. Roles of proteasomes in cell growth
5. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
6. The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications
7. Proteasome inhibition: A new strategy in cancer treatment
8. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells
9. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
10. Proteasome inhibition by the natural products epoxomicin and dihydroepoxomicin: Insights into specificity and potency
11. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- Or down-regulate antigen presentation at nontoxic doses
12. Structure of 20S proteasome from yeast at 2.4 Å resolution
13. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells